On November 5, 2025, Renaissance Group LLC initiated a new position in Halozyme Therapeutics (HALO +0.37%), acquiring 478,735 shares for an estimated $35.11 million, according to a recent SEC filing.
What happened
According to a filing with the U.S. Securities and Exchange Commission dated November 5, 2025, Renaissance Group disclosed a new position in Halozyme Therapeutics.
The fund purchased 478,735 shares during the third quarter, with a transaction value totaling $35,110,422.
The stake equates to 1.32% of the fund's $2.65 billion reportable U.S. equity assets.
What else to know
This was a new position, now representing 1.32% of Renaissance Group's reportable assets as of September 30, 2025.
The firm's top five holdings after the filing:
- Applovin (APP +1.36%): $51.4 million (1.9% of AUM)
- Alphabet (GOOGL +2.44%): $51.3 million (1.9% of AUM)
- Broadcom (AVGO +2.00%): $50.8 million (1.9% of AUM)
- Microsoft (MSFT 1.39%): $47.3 million (1.8% of AUM)
- Arista Networks (ANET 8.44%): $46.8 million (1.8% of AUM)
As of November 4, 2025, shares of Halozyme Therapeutics were priced at $68.05.
The stock delivered a 16% one-year total return, outperforming the S&P 500 by 1 percentage point over the same time.
Company overview
| Metric | Value |
|---|---|
| Market Capitalization | $8.11 billion |
| Revenue (TTM) | $1.24 billion |
| Net Income (TTM) | $595.49 million |
| Price (as of market close 11/4/25) | $68.05 |
Company snapshot
Halozyme Therapeutics:
- Offers ENHANZE drug delivery technology and Hylenex recombinant, enabling subcutaneous delivery of biologics and facilitating fluid administration; portfolio includes partnered products such as Perjeta, RITUXAN HYCELA, HYQVIA, and others addressing oncology, immunology, and rare diseases.
- Serves global biopharmaceutical partners and healthcare providers, targeting large pharmaceutical manufacturers and specialty drug markets across multiple therapeutic areas.
- Operates a scalable licensing model, generating revenue through technology partnerships and product royalties with major pharmaceutical companies.
Halozyme Therapeutics is a biotechnology company focused on drug delivery solutions, leveraging its proprietary ENHANZE platform to enable more efficient and patient-friendly administration of injectable therapeutics.
The company's licensing model and diverse portfolio of partnered products drive revenue growth and profitability, positioning it as a key enabler in the advancement of next-generation biologics and specialty therapies.
Foolish take
Renaissance Group's purchase of Halozyme Therapeutics is certainly noteworthy to investors.
Not only is this a new position for Renaissance, but Halozyme quickly becomes the firm's 29th-largest holding among its 257-stock portfolio.
Since its 2004 initial public offering, Halozyme's total returns have nearly doubled those of the S&P 500, so it has a lengthy track record of success.
The last decade has been an even bigger success for Halozyme, which has grown its sales by 38% annually over that time.
Home to numerous patents that enable subcutaneous delivery of biologics, the company has inked multiple partnerships with a who's-who list of biotech companies eager to provide Halozyme's time-saving products to its customers.
While the company's sales growth slowed to "only" 22% in the last quarter, its net income margin of 47% arms Halozyme with a war chest to use on tuck-in acquisitions and steady share repurchases.
In 2022, the company acquired Antares for $960, and recently it scooped up Elektrofi for $900.
In addition to spending on mergers and acquisitions, Halozyme has lowered its shares outstanding by 3% annually over the last five years, making it a very shareholder-friendly stock.
Trading at just 11 times forward earnings, Halozyme looks to be a fascinating purchase by Renaissance Group -- and I might have to research the promising stock more on my own as well.
Glossary
Assets Under Management (AUM): The total market value of investments managed on behalf of clients by a fund or firm.
Reportable Assets: Investments that a fund is required to disclose in regulatory filings, often U.S. publicly traded equities.
New Position: The initial purchase of a security by a fund, indicating it was not previously held.
Stake: The amount or percentage of ownership a fund or investor holds in a company.
Top Holdings: The largest investments in a fund's portfolio, typically ranked by market value.
Total Return: The investment's price change plus all dividends and distributions, assuming those payouts are reinvested.
Outperform: When an investment delivers a higher return than a benchmark or comparable index.
Biologics: Medicines derived from living organisms, often used for complex diseases like cancer or autoimmune conditions.
Therapeutic Areas: Specific categories of diseases or medical conditions targeted by pharmaceutical products.
ENHANZE Platform: Halozyme's proprietary technology enables faster and easier delivery of injectable drugs under the skin.
Licensing Model: A business approach where a company allows others to use its technology or products in exchange for fees or royalties.
TTM: The 12-month period ending with the most recent quarterly report.
